We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VNCE:NASDAQVince Holding Corp. Analysis

Data as of 2026-08-02 - not real-time

$6.33

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Vince Holding Corp. (VNCE) is trading at $6.33, just above its 20‑day SMA of 6.31 and comfortably over the 50‑day SMA of 5.85, a classic bullish alignment of moving averages. The 30‑day volatility of roughly 61% and a beta near 1.6 signal a stock that swings sharply with market moves, while an RSI of 52 indicates neutral momentum. Although the MACD histogram is negative, giving a bearish signal, the overall trend direction is flagged bullish and the price sits on a solid support level of $5.64 with resistance near $7.25. The Fear & Greed Index sits at 92.9 (“Extreme Greed”), reflecting strong market enthusiasm.
Fundamentally, VNCE trades at a forward PE of 8.8 and a price‑to‑book of 1.62, implying an upside of about 42% to the consensus $9 target. Revenue is growing at 10.5% with a healthy gross margin near 50%, but a negative operating margin, a debt‑to‑equity ratio above 260%, and negative free cash flow highlight financial strain. The stock pays no dividend, so dividend sustainability is not a factor. Analyst coverage rates VNCE as a “strong buy,” and the recent turnaround narrative adds qualitative support to the upside case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering just above the 20‑day SMA supports near‑term stability
  • MACD bearish histogram warns of a possible short‑term pullback
  • Decreasing volume raises liquidity concerns

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued valuation metrics (PE <10, P/B 1.6) provide margin of safety
  • Turnaround narrative and 42% upside to the $9 target price
  • Strong revenue growth and high gross margin support earnings potential

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Potential for improved operating efficiency could turn negative margins positive
  • High beta and volatility suggest higher reward for patient investors
  • Absence of dividend obligations and strategic brand licensing reduce cash‑flow pressure

Key Metrics & Analysis

Financial Health

Revenue Growth10.50%
Profit Margin2.97%
P/E Ratio9.0
ROE21.28%
ROA3.15%
Debt/Equity269.48
P/B Ratio1.6
Op. Cash Flow$5.9M
Free Cash Flow$-3246625

Technical Analysis

TrendBullish
RSI52.3
Support$5.64
Resistance$7.25
MA 20$6.31
MA 50$5.85
MA 200$3.81
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Target Price$9.00
Upside/Downside42.18%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.61
Volatility60.81%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.